Circulating tumor cells as a surrogate marker for determining clinical outcome to mFOLFOX chemotherapy in patients with stage III colon cancer

BACKGROUND: This study was aimed to detect post-chemotherapeutic circulating tumour cells (CTCs) in stage III colon cancer patients and identify those who were at high risk of relapse. METHODS: We used human telomerase reverse transcriptase, cytokeratin-19, cytokeratin-20, and carcinoembryonic antig...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Lu, C-Y, Tsai, H-L, Uen, Y-H, Hu, H-M, Chen, C-W, Cheng, T-L, Lin, S-R, Wang, J-Y
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2013
Matèries:
Clinical Study
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3590657/
https://ncbi.nlm.nih.gov/pubmed/23422758
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2012.595
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars